The FDA has granted Novartis’ ianalumab Breakthrough Therapy designation for Sjogren’s disease, backed by positive phase III results. The antibody targets B cells via BAFF-R blockade and could become ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results